|
May 13
|
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
|
|
May 10
|
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
|
|
May 10
|
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
|
|
May 9
|
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
|
|
May 9
|
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
|
|
May 9
|
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss
|
|
May 8
|
Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates
|
|
May 8
|
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues
|
|
May 7
|
Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
|
|
May 6
|
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
|
|
May 3
|
Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
|
|
May 2
|
Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
|
|
May 2
|
Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales
|
|
Apr 29
|
Annovis Bio Shares Tumble After Drug Candidate Buntanetap for Alzheimer's Misses Efficacy Endpoint in Phase 2/3 Study
|
|
Apr 29
|
UPDATE 3-Annovis tumbles as Alzheimer's treatment misses in mid-stage study
|
|
Apr 29
|
Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
|
|
Apr 24
|
Wall Street Analysts Believe Annovis Bio (ANVS) Could Rally 197.98%: Here's is How to Trade
|
|
Apr 23
|
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
|
|
Apr 19
|
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
|
|
Apr 19
|
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
|